Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Histone demethylase that demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Additionally we are shipping KDM5B Proteins (4) and many more products for this protein.
Showing 10 out of 130 products:
Human Polyclonal KDM5B Primary Antibody for IHC, IHC (p) - ABIN4332094
Wouters, Stas, Gremeaux, Govaere, Van den Broeck, Maes, Agostinis, Roskams, van den Oord, Vankelecom: The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis. in PLoS ONE 2013
Show all 8 references for 4332094
Human Monoclonal KDM5B Primary Antibody for WB - ABIN395143
Roesch, Fukunaga-Kalabis, Schmidt, Zabierowski, Brafford, Vultur, Basu, Gimotty, Vogt, Herlyn: A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. in Cell 2010
Show all 7 references for 395143
Mouse (Murine) Polyclonal KDM5B Primary Antibody for WB - ABIN658397
Kim, Shin, Subramaniam, Bruinsma, Kim, Hawse, Spelsberg, Janknecht: Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10. in Biochemical and biophysical research communications 2010
Show all 5 references for 658397
Human Polyclonal KDM5B Primary Antibody for ICC, IF - ABIN438013
Roesch, Vultur, Bogeski, Wang, Zimmermann, Speicher, Körbel, Laschke, Gimotty, Philipp, Krause, Pätzold, Villanueva, Krepler, Fukunaga-Kalabis, Hoth, Bastian, Vogt, Herlyn: Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. in Cancer cell 2013
Show all 4 references for 438013
Human Monoclonal KDM5B Primary Antibody for IF, IHC (p) - ABIN1327126
Xiang, Zhu, Han, Ye, Xu, Peng, Ma, Yu, Lin, Chen, Chen: JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. in Proceedings of the National Academy of Sciences of the United States of America 2007
Show all 3 references for 1327126
Human Polyclonal KDM5B Primary Antibody for FACS, ICC - ABIN4332096
Croteau, Jenkins, Ye, Mullins, Brinckerhoff: Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma. in Journal of cellular physiology 2013
Show all 2 references for 4332096
Human Monoclonal KDM5B Primary Antibody for ELISA, WB - ABIN524186
Hayami, Yoshimatsu, Veerakumarasivam, Unoki, Iwai, Tsunoda, Field, Kelly, Neal, Yamaue, Ponder, Nakamura, Hamamoto: Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. in Molecular cancer 2010
We established the function of JARID1B in mediating the cancer stem cell potential of G0-like cells and our results expand understanding of its context-specific roles in malignant and normal stem cell homeostasis
KDM5B is up-regulated in esophageal squamous cell carcinoma cells.MiR-194 targets KDM5B to inhibit esophageal squamous cell carcinoma development and progression.
Study identified USP15 (show USP15 Antibodies) as having recurrent de novo loss of function mutations and discovered evidence supporting two other known genes with recurrent de novo variants (FOXP1 (show FOXP1 Antibodies) and KDM5B).
research suggests that miR424-5p may act as a novel anti-oncogene (show RAB1A Antibodies) in cervical cancer by blocking cell growth through targeting KDM5B-Notch (show NOTCH1 Antibodies) pathway
JARID1B is involved in the pathogenesis of glioma.
PLU-1 was overexpressed in colorectal cancer tissue compared with healthy colon. PLU-1 expression positively correlated with colorectal cancer progression.
Hsa-miR-448 disrupting KDM5B-MALAT1 signalling axis and associated activities in TNBC cells, projects it as a putative therapeutic factor for selective eradication of TNBC cells.
data indicate that parallel immunohistochemical assays of the expression levels of all the isoforms and of the RBP2-H1 variant of JARID1B may be an efficient technique of differentiating between benign naevi and melanomas
KDM5B, a histone demethylase (show MBD2 Antibodies) known to be involved in breast cancer tumorigenesis, as a target of miR (show MLXIP Antibodies)-137.
Data show that KDM5B is frequently up-regulated in hepatocellular carcinoma tissues and cell lines and correlated with poor prognosis. Its depletion leads to highly impaired clonogenesis and cell cycle arrest through up-regulation of p15 (show CDKN2B Antibodies) and p27 (show PAK2 Antibodies).
data suggest Kdm5b negatively regulates neurogenesis and represses reelin (show RELN Antibodies) in neural stem cells from the adult subventricular zone.
These results suggest that KDM5B acts to repress type I IFN and other innate cytokines to promote an altered immune response following Respiratory syncytial virus infection that contributes to development of chronic disease.
findings demonstrate that dissociation of the GAPDH/Siah1 pro-apoptotic complex can block high glucose-induced pericyte apoptosis, widely considered a hallmark feature of DR
Deletion of Jarid1b compromises hematopoietic stem cell (HSC (show FUT1 Antibodies)) self-renewal capacity; Jarid1b is a positive regulator of HSC (show FUT1 Antibodies) potential.
Mechanistically, JARID1B was required for GATA3 (show GATA3 Antibodies) recruitment to the Foxa1 (show FOXA1 Antibodies) promoter to activate Foxa1 (show FOXA1 Antibodies) expression.
KDM5B is a barrier to the reprogramming process as evidenced by the accelerated reprogramming of differentiated cells in the absence of Kdm5b.
these studies identified Jarid1b as a negative regulator of hematopoietic stem cell (HSC (show FUT1 Antibodies)) activity and Jhdmlf as a positive regulator of HSC (show FUT1 Antibodies) activity.
Results suggest a role for Jarid1b in Rb-mediated repression of cell cycle genes during senescence.
results delineate an essential role for Jarid1b-mediated transcriptional control during embryonic stem cell differentiation
The present study demonstrated a functional contribution of PLU1 overexpression with concomitant epigenetic dysregulation in cancer progression.
Histone demethylases KDM3A (show KDM3A Antibodies), KDM4A (show KDM4A Antibodies), and KDM4C (show KDM4C Antibodies) were expressed before and after embryonic genome activation, whereas KDM5B was mainly expressed during the blastocyst period.
Histone demethylase that demethylates 'Lys-4' of histone H3, thereby playing a central role in histone code. Does not demethylate histone H3 'Lys-9' or H3 'Lys-27'. Demethylates trimethylated, dimethylated and monomethylated H3 'Lys-4'. Acts as a transcriptional corepressor (By similarity).
jumonji, AT rich interactive domain 1B (Rbp2 like)
, jumonji, AT rich interactive domain 1Ba (Rbp2 like)
, histone demethylase JARID1B-B
, jumonji/ARID domain-containing protein 1B-B
, lysine-specific demethylase 5B-B
, putative DNA/chromatin binding motif
, lysine (K)-specific demethylase 5B
, Jumonji, AT rich interactive domain 1B (RBP2-like)
, jumonji, AT rich interactive domain 1B
, lysine-specific demethylase 5B-like
, cancer/testis antigen 31
, histone demethylase JARID1B
, jumonji/ARID domain-containing protein 1B
, lysine-specific demethylase 5B
, retinoblastoma-binding protein 2 homolog 1
, retinoblastoma-binding protein 2, homolog 1A
, putative DNA/chromatin binding motif 1